Innotox / INNOTOX 50 units. is an innovative drug (botulinum toxin) type A developed by the South Korean company Medytox Inc.

This drug has gained great popularity in clinics in South Korea and Japan due to several advantages:

1) Structure of the drug: Innotox is available in a new liquid phase, so it does not require dilution. One bottle contains a ready-made product solution for 50 units.

2) Composition: the improved formula of the preparation does not contain: proteins, albumin, gelatin, compared with other similar drugs.

3) Temperature conditions: insensitive to temperature extremes, in contrast to solid-phase preparations. However, it is recommended that you keep it in the refrigerator until use. The opened bottle can be stored in the refrigerator at a temperature of 2 to 8 degrees 72 hours.

4) Diffusion: has the least diffusion among all botul tox currently known.

5) Effect: during the course of procedures, the effect lasts up to 8 months, in contrast to other botul tox, in which the effect lasts up to 4 months.

The active components are: botu tox t A, L-methionine, polysorbate 20, buffered saline phosphate pH 7.0.

Indications

- blepharospasm;

- hemifacial spasm;

- cervical dystonia (spastic torticollis);

- focal spasticity of the wrist and hand in stroke patients;

- paralytic strabismus (squint);

- local muscle spasm in cerebral palsy in children aged 2 years and older;

- correction of facial wrinkles.

ACTIVE COMPONENTS

botul tox type A,

L-methionine,

polysorbate 20,

buffered saline phosphate pH 7.0.

CONTRAINDICATIONS, COMPLICATIONS, POSSIBLE SIDE EFFECTS:

hypersensitivity to the components of the composition;

pregnancy and lactation;

inflammatory processes on the skin in the target area;

bleeding disorders;

herpes, as well as any infectious and chronic systemic diseases in the acute stage;

fever;

diabetes;

oncological diseases;

pronounced hernial protrusions on the lower and upper eyelids;

myasthenia gravis (Myasthenia Gravis) - an autoimmune disease that causes chronic muscle fatigue syndrome;

age before 18 and after 65 years.

MODE OF APPLICATION

A solution of the finished product is injected with a 30G needle at the rate of 4 units per 0.1 ml (regardless of the volume of syringe used).

Injections of the drug should be carried out by a qualified doctor who has undergone a training course.